Global Immune Checkpoint Inhibitors Market Report, History and Forecast 2015-2026, Breakdown Data by Manufacturers, Key Regions, Types and Application

Immune checkpoints are proteins that play an important role in regulating the immune system. In cancer, the immune checkpoints are activated to suppress the anti-tumor activity of the immune system thereby suppressing the immune response against the cancer cells. The study of these proteins and pathways has led to the development of a number of immune checkpoint inhibitors as therapies against cancer. Initial preclinical studies showed that antibody blockade of the immune checkpoint molecule CTLA-4 resulted in successful anti-tumor immune responses in the murine cancer models. This was then followed by studies targeting the PD-1/PD-L1 pathway. Ipilimumab and Yervoy were the first immune checkpoint inhibitors introduced in the market. With the promising results of Yervoy, several anti-PD-1 and anti-PD-L1 antibodies have been developed. Although there are number of other checkpoints that have been studied, such as LAG-3 and TIM-3, the only approved immune checkpoint inhibitors include CTLA-4, PD-1 and PD-L1.

Market Analysis and Insights: Global Immune Checkpoint Inhibitors Market
The global Immune Checkpoint Inhibitors market size is projected to reach US$ 36030 million by 2026, from US$ 14730 million in 2020, at a CAGR of 16.1% during 2021-2026.
Global Immune Checkpoint Inhibitors Scope and Segment
The global Immune Checkpoint Inhibitors market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Immune Checkpoint Inhibitors market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
The major regions covered in the report are North America, Europe, Asia-Pacific, South America, Middle East & Africa, etc. The report has specifically covered major countries including U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc. It includes revenue and volume analysis of each region and their respective countries for the forecast years. It also contains country-wise volume and revenue from the year 2015 to 2020. Additionally, it provides the reader with accurate data on volume sales according to the consumption for the same years.

Segment by Type, the Immune Checkpoint Inhibitors market is segmented into
PD-1/PD-L1
CTLA-4

Segment by Application, the Immune Checkpoint Inhibitors market is segmented into
Lung Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Melanoma
Blood Cancer
Other

Immune Checkpoint Inhibitors market competitive landscape provides details and data information by players. The report offers comprehensive analysis and accurate statistics on revenue by the player for the period 2015-2020. It also offers detailed analysis supported by reliable statistics on revenue (global and regional level) by players for the period 2015-2020. Details included are company description, major business, company total revenue and the sales, revenue generated in Immune Checkpoint Inhibitors business, the date to enter into the Immune Checkpoint Inhibitors market, Immune Checkpoint Inhibitors product introduction, recent developments, etc.
The major vendors covered:
Bristol Myer Squibb
AstraZeneca
Merck & Co.
Roche / Genentech
Incyte Corporation
NewLink Genetics
ArGEN-X
Seattle Genetics
Pfizer
MacroGenics
Celldex Therapeutics
CureTech
Immutep
Innate Pharma
Sorrento Therapeutics
GlaxoSmithKline
GITR, Inc

Geographic Segmentation
The report offers exhaustive assessment of different region-wise and country-wise Immune Checkpoint Inhibitors markets such as U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E, etc. Key regions covered in the report are North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa.
For the period 2015-2026, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Immune Checkpoint Inhibitors market. For the period 2015-2020, it provides sales (consumption) analysis and forecast of different regional markets by Application as well as by Type in terms of volume.